Find Clinical Trials

Breast cancer survivors: Inclusion Criteria: * biological sex: woman * able to speak and understand English * have a diagnosis of a breast cancer * have completed primary curative cancer treatments (i.e., surgery, radiation, chemotherapy) except for hormonal therapies (e.g., aromatase inhibitors) or trastuzumab a minimum of 3 months and a maximum of 5 years before starting CBCT or the control * have a supportive partner (aka caregiver) who can participate with them Exclusion Criteria: * nursing home resident * have ongoing (1 or more meditation sessions per week) or past regular meditation experience in the last 4 years (i.e., more than two meditation sessions \[completed or attempted\] per year, either with a group or individually, to be evaluated by the Principal Investigator) Supportive partners (aka informal caregivers) Inclusion Criteria: * named by the survivor * live in the same household as the survivor * able to speak and understand English Exclusion Criteria: * have ongoing (1 or more meditation sessions per week) or past regular meditation experience in the last 4 years (i.e., more than two meditation sessions \[completed or attempted\] per year, either with a group or individually, to be evaluated by the Principal Investigator)

Inclusion Criteria: * Diagnosis of major depressive disorder or bipolar II * Clinical indications for ECT with right unilateral electrode placement Exclusion Criteria: * Defined neurological or neurodegenerative disorder (e.g., traumatic brain injury, epilepsy, Alzheimer's disease) * Other psychiatric conditions (e.g., schizophrenia, bipolar I disorder) * Current drug or alcohol use disorder (except for nicotine) * Contraindications to MRI.

Inclusion Criteria: * Female * age at the MRI examination from 18-90 years Exclusion Criteria: * insufficient image quality as judged by a blinded radiologist before start of the analysis * non-identifiably ground truth (i.e., diagnosis has not yet been established)

Inclusion Criteria: 1. 1\. Aged between 18 and 80 years. 2. No previous diagnosis of Celiac Disease, Ulcerative Colitis, Crohn's disease, IBS, Functional Dyspepsia, and T2D by participant self-report (Control group). 3. Prior diagnosis of Celiac Disease, Ulcerative Colitis, Crohn's disease, IBS, or Functional Dyspepsia, and T2D by a relevant physician, nutritionist, naturopath, etc, and willingness to provide documentation to confirm this diagnosis or have a consultation with the PI. (Disease group). 4. Ability to understand and provide informed consent. 5. Ability and willingness to meet the required schedule, study interventions, and questionnaire requirements. 6. No planned change in diet or medical interventions during the study duration. Exclusion Criteria 1. Known disease which, in the investigator's opinion, would lead to intestinal structuring or obstruction with a risk of capsule non-excretion (particular diseases which would be assessed on a case-by-case basis would include, achalasia, eosinophilic esophagitis, cancer diagnosis or treatment within the past year, or previous esophageal, gastric, small intestinal, or colonic surgery. Appendectomy or cholecystectomy more than 3 months prior to enrollment are acceptable). The main deciding factor would be a history of obstructive symptoms in the previous 3 months prior to entry. 2. Use of any medications or having undergone procedures in the previous week that could substantially alter gastrointestinal motor function (e.g., opioids, anticholinergics, laxatives, or GLP-1 analogues). 1. Stimulant laxative use (includes bisacodyl/Dulcolax, senna/Senekot, cascara, or fibre supplments) is allowed if it is kept unchanged in the week prior to the SIMBA Capsule ingestion. Osmotic laxatives (polyethylene glycol (PEG; other trade names), milk of magnesia, lactulose), stool softeners (docusate; other trade names) or secretagogues (linaclotide/Constella, plecanatide/Trulance, tenapanor/Ibsrela should not be used within 7 days of taking the SIMBA capsules. 2. Prokinetics use is allowed if kept unchanged in the week prior to the SIMBA Capsule ingestion (includes domperidone, metoclopramide, prucalopride). Inconsistent use of prokinetics will be evaluated by the PI. 3. PPI or H2RA use. Must be able to discontinue PPI or H2RA medications 48hrs prior to SIMBA capsule ingestion, medication can be resumed 4 hours after ingestion. 3. History of oropharyngeal dysphagia or other swallowing disorder with a risk of aspiration of the capsule. 4. History of known structural gastrointestinal abnormalities such as strictures or fistulas leading to mechanical obstruction 5. History of abdominal radiation treatment 6. Females of childbearing age who are pregnant or lactating by self-report. (should an X-ray be required for confirmation of capsule passage, a urine pregnancy test will be administered beforehand). 7. No antibiotics, or colon cleanses/bowel prep for 2 weeks. 8. \< 2 bowel movements per week (Control Group only).

Inclusion Criteria: * Patients over 18 years of age with: * diabetes. Exclusion Criteria: * Exclusion criteria: None.

Inclusion Criteria: * For participants across all three aims are: * Female sex * Aged 15+ * Pregnant and presenting antenatal care at the Gugulethu MOU * HIV-negative * Recent PrEP initiation (\<1 month ago) or PrEP adherence challenges, either documented (\>2 weeks late to pick up PrEP refill) or self-reported * Moderate to severe symptoms of posttraumatic stress and/or depression (defined as a score of ≥31 on PTSD Checklist for DSM-5 (PCL-5) and/or a score of ≥13 on the Edinburgh Postnatal Depression Scale (EPDS). Cutoff scores may be adjusted by 3-5 points to facilitate recruitment. Exclusion Criteria: * There are no exclusion criteria with respect to parity or gravidity. * Participants who are unable to provide informed consent or assent in English or Xhosa * Have a significant psychiatric illness (e.g., active psychotic disorder or untreated bipolar disorder) that could interfere with participation will be excluded. Positive symptoms of active psychosis or mania will be assessed by the research assistants. They will be trained to identify delusions, hallucinations, disorganized or pressured speech, flight of ideas, and grandiosity as they speak to potential participants. * Potential participants will also be asked if they have any health conditions that make it difficult for them to travel to the clinic.

Inclusion Criteria: * Female Sex * Between 25-55 years of age * Ontario resident with a valid OHIP card A prior or current diagnosis of: * Pre-eclampsia, eclampsia, gestational hypertension * Gestational diabetes * Primary ovarian insufficiency (menopause \< age 40) * Early menopause (menopause between ages 40-45) * Polycystic ovarian syndrome (PCOS) * Rheumatologic inflammatory disorders (Lupus, Rheumatoid Arthritis, Psoriatic Arthritis) * Breast cancer OR No prior history of sex-specific or female-predominant risk factors outlined in the SSR group Exclusion Criteria: * Male sex * Currently pregnant * Prior diagnosis of any of the following: * CVD including coronary heart disease, heart failure, congenital heart disease, stroke/transient ischemic attack, valvular heart disease, peripheral vascular disease, aortapathy, atrial fibrillation or flutter, other CVD * Neurodegenerative disease known to affect the heart (e.g., muscular dystrophy) * Untreated serious mental illness (e.g., untreated psychosis)

Inclusion Criteria: * Documented informed consent from legal guardian and assent from participant as appropriate. * Children 8 to 17 years of age with obesity (BMI ≥ 95th percentile for age and sex) and mild asthma. * Participants (or parent/guardian) must have access to the internet and an approved smart device/computer. * Child must have a designated caregiver who expresses a commitment to encourage the participant to complete the study procedures. * Participant and legal guardian must speak and read English. * Child is currently taking prescription medicine for asthma (Any type of albuterol or inhaled steroid) Exclusion Criteria: * Prior intubation for asthma * Current self-reported pregnancy or planning to become pregnant. * Have an FEV1 \< 50% of predicted at screening * History of lung surgery in the past two years, * History of pulmonary embolism in the past two years, * Any history of recurrent spontaneous pneumothorax, or pneumothorax in the past 12 months * Current undiagnosed chest pain, * History of inner ear surgery in the past 12 months, * Undiagnosed syncopal episodes in the past two years, * Progressive neurological or neuromuscular disorders or need for chronic O2 therapy. * Inability to complete baseline measurements satisfactorily according to the research coordinator's or PI's judgment. * Any condition in the opinion of the PI that would not allow safe conduct of study procedures (including IMR, MIP testing or step-test), such as a physical disability, recent musculoskeletal injury or illness, current and ongoing evaluation for undiagnosed cardiopulmonary or neurologic symptoms

Inclusion Criteria: * Diagnosed with MDD by a trained research assistant according to the criteria outlined in the DSM-5 * Ability to provide informed consent * Ability to speak and read English * Having consistent and reliable access to the internet Exclusion Criteria: * Active psychosis * Acute mania * Severe alcohol, or substance use disorder * Active suicidal or homicidal ideation * Currently receiving psychotherapy

Inclusion Criteria: * Male and female participants who completed end of treatment study visit in Study INS1009-201, INS1009-202, or any other lead-in PAH TPIP study. Participants for whom the OLE study was not available at the time of their completion of the lead-in study are eligible for enrolment within one year of their lead-in end of treatment visit. * Complete baseline screening assessments to confirm eligibility to participate if more than 30 days have elapsed since the end of the study visit in Study INS1009-201, INS1009-202, or any other lead-in PAH TPIP study. Exclusion Criteria: * Initiation of parenteral administration of prostacyclin analogues (eg, TRE, epoprostenol) since the completion of studies INS1009-201, INS1009-202 or other TPIP studies. Initiation of inhaled prostacyclin analogues (eg, TRE \[Tyvaso\] or iloprost) and oral prostacyclin analogues (eg, TRE \[Orenitram\]) or receptor agonists (eg, selexipag) are permitted if stopped 24 hours prior to the start of study drug administration. * Any new ventricular or supraventricular tachyarrhythmia except for paroxysmal atrial fibrillation and any new symptomatic bradycardia. * New-onset of heart disease including left ventricular ejection fraction (LVEF) ≤40% or clinically significant valvular, constrictive, or symptomatic atherosclerotic heart disease (eg, stable angina, myocardial infarction, etc). * New evidence of thromboembolic disease as assessed by ventilation/perfusion (VQ) scan, pulmonary angiography, or pulmonary computed tomography (CT) scan. * Active and current symptomatic coronavirus disease 2019 (COVID-19) or previous severe disease and/or hospitalization due to COVID-19. * Interval organ transplantation. * New active liver disease or hepatic dysfunction. * Interval malignancy with exception of completely treated in situ carcinoma of the cervix and completely treated non-metastatic squamous or basal cell carcinoma of the skin. * Use of any investigational drug/device or participation in any investigational study within 30 days prior to screening, not including TPIP of the lead-in study. * Current use of cigarettes (as defined by Centers for Disease Control and Prevention \[CDC\]) or e-cigarettes: An adult who has smoked at least 100 cigarettes in his or her lifetime, who smokes either every day or some days. * Participants who currently inhale marijuana (recreational or medical). Note: Other inclusion/exclusion criteria may apply.

Inclusion Criteria Patients must satisfy all of the following criteria to be included in the study: 1. Informed of the trial before the start of the trial and voluntarily sign their name and date on the informed consent form 2. Aged ≥18 years 3. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 2 4. Adequate organ and bone marrow function, defined as follows: * Hemoglobin ≥9.0 g/dL (have not received blood transfusion or erythropoietin treatment within 14 days before the first dose) * Absolute neutrophil count ≥1.5 × 109/L (have not received granulocyte colony-stimulating factor or granulocyte-macrophage colony-stimulating factor treatment within 14 days before the first dose) * Platelet count ≥100 × 109/L if no demonstrable hepatic metastases or ≥75 × 109/L in the presence of hepatic metastases (have not received platelet transfusion, thrombopoietin, or interleukin-11 treatment within 14 days before the first dose) * TBIL ≤1.5 × ULN if no demonstrable hepatic metastases or ≤3 × ULN in the presence of hepatic metastases * ALT and AST ≤3 × ULN if no demonstrable hepatic metastases or ≤5 × ULN in the presence of hepatic metastases * Serum albumin ≥2.5 g/dL * Creatinine clearance ≥60 mL/min (calculated according to Cockcroft Gault formula) * Activated partial thromboplastin time and international normalized ratio ≤1.5 × ULN, except for patients receiving anticoagulant therapy, who must have international normalized ratio within therapeutic range as deemed appropriate by the investigator 5. Female patients of childbearing potential must agree to use a highly effective form of contraception and not donate, or retrieve for their own use, ova from the time of screening and throughout the study period, and for at least 6 months after the last dose of study drug. Male patients must agree to use a highly effective form of contraception and not freeze or donate sperm from the time of screening and throughout the study period, and for at least 6 months after the last dose of study drug. 6. Life expectancy of ≥3 months 7. Able and willing to comply with protocol visits and procedures 8. For NSCLC patients: * Have a histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC not amenable to curative surgery or radiation * Have a documentation of an EGFR-activating mutation (exon 19 deletion or L858R) detected from tumor tissue at diagnosis or thereafter. Participants who have this EGFR mutation detected from blood sample may be eligible on a case-by-case basis after discussion with the sponsor. * Have documentation of disease progression on or after, or are intolerant to most recent treatment regimen for locally advanced or metastatic disease. Participants must have received all of the following: * Prior treatment with a regimen containing a 3rd-generation EGFR TKI (e.g., osimertinib). Patients receiving a 3rd-generation EGFR TKI at the time of signing informed consent should continue to take the EGFR TKI until 5 days prior to Cycle 1 Day 1 * Systemic therapy with at least 1 platinum-based chemotherapy regimen * Participants in the US must have also received prior treatment with an anti-PD-(L)1 antibody, unless they have high-risk factors indicating preferable avoidance of anti-PD-(L)1 therapy (e.g., intolerance or lack of efficacy is anticipated) Note: Patients who received platinum-based chemotherapy concurrently with anti-PD-(L)1 antibody as one regimen are eligible. For BC patients: * Have a histologically or cytologically confirmed diagnosis of unresectable locally advanced or metastatic HR-positive and HER2-negative (IHC 0, 1+, 2+/ISH-) BC (per American Society of Clinical Oncology-College of American Pathologists \[ASCO-CAP\] guidelines) * Have documentation of disease progression on or after, or were intolerant to at least 1 prior line of endocrine therapy in combination with a CDK4/6 inhibitor * Have received 0-4 lines of chemotherapy regimens (including ADCs) for locally advanced or metastatic disease Note 1: Prior treatments with PI3K inhibitors, mTOR inhibitors, AKT inhibitors, and PARP inhibitors are allowed. Note 2: If a patient develops disease relapse/progression during or within 6 months after the end of the (neo-)adjuvant therapy, or radical radiotherapy and chemotherapy, the treatment regimen will be counted as one line of treatment for locally advanced or metastatic disease, for the purpose of this inclusion criteria. 9. Have at least 1 measurable tumor lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 10. Willing to provide archival or fresh tumor tissue samples for assessment of HER3 expression level. Patients who are not able to provide tumor samples or have inadequate samples may be eligible after discussion with the sponsor. Exclusion Criteria Patients who meet any of the following criteria will be disqualified from entering the study: 1. Prior treatment with an agent targeting HER3 (including antibody, ADC, chimeric antigen receptor T cell \[CAR-T\], and other drugs) 2. Intolerant to prior treatment with a topoisomerase I inhibitor or an ADC that consists of a topoisomerase I inhibitor, including but not limited to topotecan, irinotecan, and DXd (e.g., severe diarrhea) 3. Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study 4. Inadequate washout period for prior anticancer treatment before the first dose of study drug, defined as follows: * Any cytotoxic chemotherapy or small molecular-targeted therapy (other than EGFR TKI) \<2 weeks or 5 half-lives, whichever is shorter * Endocrine therapy \<3 weeks * Monoclonal antibodies or other biological therapy \<3 weeks * Herbal medicine with antitumor indications \<2 weeks * Whole brain radiation therapy \<2 weeks or stereotactic brain radiation therapy \<1 week * Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation \<4 weeks or palliative radiation therapy \<2 weeks 5. Undergone major surgery (not including diagnostic surgery) within 4 weeks before the first dose of study drug or expect major surgery during the study 6. Prior allogeneic bone marrow transplantation or solid-organ transplantation 7. Received systemic steroids (\>20 mg/day of prednisone or its equivalent) or other immunosuppressive therapy within 2 weeks before the first dose of study drug. The following are exceptions to this criterion: * Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection) * Systemic steroids at physiological doses as replacement therapy (e.g., physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency) * Steroids as premedication for hypersensitivity reactions (e.g., computed tomography \[CT\] scan premedication) or steroids as antiemetic premedication 8. Received any live vaccine within 4 weeks before the first dose of study drug or intend to receive a live vaccine during the study 9. A history of leptomeningeal carcinomatosis 10. Brain metastases or spinal cord compression unless asymptomatic or treated and stable off steroids and anti-convulsants for at least 2 weeks before the first dose of study drug 11. Uncontrolled or clinically significant cardiovascular disease, including but not limited to: * Medical history of symptomatic congestive heart failure (New York Heart Association class II to IV) or any arterial thromboembolic event (e.g., myocardial infarction, unstable angina, cerebrovascular accident, and transient ischemic attack) within 6 months before the first dose * Uncontrolled hypertension, defined as systolic blood pressure (SBP) \>160 mm Hg and/or diastolic blood pressure (DBP) \>100 mm Hg after antihypertensive therapy * Serious cardiac arrhythmia that req

Arm 1: BPD±PH: Inclusion Criteria: * Born ≤ 30 weeks at birth * Post-menstrual age (PMA) ≥ 32 weeks * Echocardiographic evidence of PH for infants with BPD+PH. * On invasive or non-invasive ventilation with RSS \>2.0 for \>12hours/day for at least 48 hours as an early predictor of evolving BPD * Informed written consent (parents/substitute decision maker) Exclusion Criteria * Congenital Heart Disease \[Exceptions: small atrial septal defect (ASD), small ventricular septal defect (VSD), small patent ductus arteriosus (PDA)\] * Infants with pulmonary vein stenosis * Concurrent sepsis with hemodynamic instability * Infants considered likely to die within next 7 days * Any other condition that, in the opinion of the investigator, may adversely affect the infant's ability to complete the study or its measures or pose significant risk to the infant Arm 2: surgical NEC Inclusion Criteria: * Born ≤ 30 weeks at birth * Recovering from Stage IIIb NEC as per modified Bell's staging (pneumoperitoneum requiring surgery) * Tolerating 50 ml/kg/day of enteral feeds * Informed written consent (parents/substitute decision maker) * Considered medically stable by clinical team Exclusion Criteria * Congenital heart disease (except small ASD, small VSD and non hsPDA) * Pulmonary vein stenosis * Concurrent sepsis with hemodynamic instability * Likely to die within next 7 days * Other condition significantly affecting pulmonary function independent of prematurity or NEC

Inclusion Criteria: 1. Eisenmenger syndrome in functional class II, III or IV (World Health Organization for Pulmonary Hypertension). 2. Using or not oral anticoagulation with warfarin. Exclusion Criteria: 1. Hospitalized. 2. History of relevant and/or repetitive bleeding. 3. Relevant comorbidities with specific treatments. 4. Systemic syndromes, except Down syndrome. 5. Candidates for surgical treatment of any nature, except dental. 6. Clinically manifest systemic infectious or inflammatory disease. 7. Thrombocytopenia (\<80x10\*9 platelets/L). 8. Patients in chronic anticoagulation regimen other than warfarin. 9. Diabetics individuals. 10. Pregnancy in progress, interruption of contraception or amenorrhea. 11. History of intolerance of pentoxifylline or other xanthine derivatives. 12. "Creatinine clearance" less than or equal to 30 mL/minute.

Inclusion Criteria: * 1\) HD patient with at least three months since treatment initiation * 2\) Beck Depression Inventory-II (BDI-II) score ≥11 * 3\) age 21 or older * 4\) visual and audio acuity to immerse in our VR world * 5\) fluent in English or Spanish Exclusion Criteria: * 1\) unavailable for study period * 2\) prevalent cognitive impairment denoting dementia * 3\) physical limitation restricting use of a head-mounted display * 4\) history of epilepsy, seizures, or vertigo.

Inclusion Criteria: * Type 1 or Type 2 Diabetes Mellitus * Age 20-60 years (Male/Female) * Body mass index 20-30 kg/m2 * Suitable for liposuction * Condition or Disease: Diabetic Neuropathy * Wound Type: Chronic foot ulcer * Approx. wound area: 2 cm2 - 8 cm2 * Wound Condition should be of Wagner's grade I (Limited to soft tissue) * Duration of wound persistence: 6-24 Weeks * Transcutaneous oxygen pressure \> 30 mmHg, and an ankle brachial pressure index \> 0.5. * Already following an adequate off-loading method * Provided signed informed consent Exclusion Criteria: * Uncontrolled hyperglycemia (HbAlc \> 9%) * Presence of severe clinical sign of infection * Inability to tolerate off-loading, and poor prognosis diseases including malignant tumors. * Serious chronic disease i.e hepatic, heart, renal, pulmonary diseases * Patients with critical limb ischemia and osteomylitis * Withdrawal of informed consent

Inclusion Criteria: 1. Newly referred patient with CTEPH or chronic thromboembolic pulmonary disease (CTEPD) without PH according to the following criteria: 1. Mean pulmonary arterial pressure (mPAP) \> 20 mmHg at rest with pulmonary vascular resistance (PVR) \> 2 Wood units (WU); or if mPAP ≤ 20 mmHg or PVR ≤ 2 WU at rest, have exercise limitations from CTEPD without PH 2. Abnormal ventilation perfusion scan, pulmonary angiogram, computer tomographic pulmonary angiogram, or magnetic resonance pulmonary angiogram confirming CTEPD as recommended by standard guidelines 2. Treatment with anticoagulation for ≥ 3 months before diagnosis of CTEPH or CTEPD without PH 3. Naïve to interventional treatment (both PEA and BPA) 4. Pre-treatment with PH-specific medication for ≤ 12 months, or no medical pre-treatment, at enrollment 5. Willing and able to provide informed consent in order to participate in the study (informed consent signed) 6. Age ≥ 18 years 7. CTEPH-specific treatment must be modified or initiated at the participating site Exclusion Criteria: 1. Main cause of PH other than CTEPH 2. Participating in an interventional clinical trial at enrollment

Inclusion Criteria: * Age must be 60 years or more * Diagnosed with T2DM by physician minimum for more than 1 year * The ability to communicate in Malay or English language properly * The ability to perform daily activities independently * No major complications (e.g.- dementia, blind, deaf) * Planned to continue receiving care at this clinic for next 6 months * Participated at the usual education session * Access to a smart phone with internet Exclusion Criteria: * Debilitating medical or related condition (e.g. end-stage cancer, severe mental illness) * Physical inability to provide self-care

Inclusion Criteria: 1. aged 18-75 years; 2. living in the province where the hospital is located in the last three years; 3. with a medical diagnosis of one of the target diseases; 4. willing to provide written informed consent. Exclusion Criteria: 1. female in pregnancy or lactation(unless the subject is pregnant women); 2. with medical diagnoses of other serious illnesses; 3. with a history of bariatric surgery or intestinal resection, except for appendectomy； 4. individual who was treated with drugs in the preceding 1 month, including antibiotics, metformin, statins, acid inhibitor, probiotics, and probiotics; individuals having consumed yogurt more than 3 times in the preceding 1 month; heavy drinkers who have consumed more than 4 taels of liquor or 1000ml of beer; frequent alcohol consumers who have drunk per week in the last month.

Inclusion Criteria: 1. Female patients aged 18 -75 ; 2. Willing to receive LHRH agonist therapy (premenopausal patients only); 3. All patients were histopathologically confirmed to be estrogen receptor (ER) -positive and HER2-positive. 4. Treatment-naïve stage II-III patients with tumor stage meeting AJCC version 8 criteria; 5. ECOG score 0-1; 6. Organ function level must meet the following requirements: (1) bone marrow function • ANC ≥ 1.5 x 109/L ; • PLT ≥ 100 × 109/L • Hb ≥ 90 g/L ; (2) hepatic and renal function • TBIL ≤ 1.5 × ULN; • AL and AST ≤ 3 × ULN (ALT and AST ≤ 5 × ULN in patients with liver metastases); • BUN and Cr ≤ 1.5 × ULN and creatinine clearance ≥ 50 mL/min; (Cockcroft-Gault formula) (3) Echocardiography: LVEF ≥ 50%; (4) 12-lead ECG: QT interval ≤ 480 ms; 7. Able to undergo needle biopsy; 8. Voluntarily join this study to sign informed consent, have good compliance and willing to cooperate with follow-up. Exclusion Criteria: 1. Received any form of anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.); 2. Received any other anti-tumor therapy at the same time; 3. Bilateral breast cancer, inflammatory breast cancer or occult breast cancer; 4. Stage IV breast cancer; 5. Breast cancer without histopathological diagnosis; 6. Other malignant tumors in the past 5 years, except cured cutaneous basal cell carcinoma and cervical carcinoma in situ; 7. Severe heart, liver and kidney and other vital organ dysfunction; 8. Inability to swallow, chronic diarrhea and intestinal obstruction, there are a variety of factors affecting drug administration and absorption; 9. Participated in other drug clinical trials within 4 weeks before enrollment; 10. Known history of hypersensitivity to the drug components of this protocol; history of immunodeficiency, including positive HIV test, HCV, active viral hepatitis B or other acquired, congenital immunodeficiency diseases, or history of organ transplantation; 11. Had any cardiac disease, including: (1) cardiac arrhythmia requiring medication or clinically significant; (2) myocardial infarction; (3) heart failure; (4) any other cardiac disease judged by the investigator to be inappropriate for participation in this trial; 12. Female patients who are pregnant or lactating, female patients of childbearing potential with a positive baseline pregnancy test, or female patients of childbearing age who are unwilling to take effective contraceptive measures throughout the trial; 13. According to the investigator 's judgment, there are concomitant diseases that seriously jeopardize the patient' s safety or affect the patient 's completion of the study (including but not limited to uncontrolled severe hypertension, severe diabetes, active infection, etc.); 14. Had a documented history of neurological or psychiatric disorders, including epilepsy or dementia.Any other condition that, in the opinion of the investigator, would make the patient inappropriate for participation in this study.

Inclusion Criteria: 1. Patient aged ≥ 18 years 2. Severe asthma diagnosed by a pulmonologist and followed for at least a year 3. Blood eosinophilia ≥ 0.15 G / L in the 12 months preceding inclusion in the trial. 4. At least 2 exacerbations in the past 12 months, each time treated with oral corticosteroid therapy or an increase in dosage of oral corticosteroid therapy prescribed for a long time, for at least 72 hours. 5. High dose inhaled corticosteroid therapy (\> 800 μg / d budesonide,\> 500 μg / d fluticasone,\> 1000 μg / d beclometasone, etc.) and at least one second controller asthma treatment with Long-Acting Beta-Agonists or Long-Acting Muscarinic Antagonists 6. Patient must have an efficient contraception method 7. Patient affiliated to a social security scheme. 8. Patient able to give free, informed and written consent. Exclusion Criteria: 1. Pregnant woman (urinary beta-HCG positive at inclusion) or breastfeeding 2. Active smoking or ex-smoking for less than 6 months and more than 10 pack-years 3. Exacerbation in the 4 weeks preceding first Mepolizumab injection 4. Patient who has already been treated with Mepolizumab or another anti-IL-5 or -5R treatment 5. Patient currently using a biotherapy indicated in severe asthma other than anti-IL5 or 5R treatments or stopped for less than 2 months 6. Treatment underway with another biotherapy not indicated for severe asthma 7. Patient participating in other interventional research, excluding routine care research (old regulation) and category 2 research not interfering with primary endpoint analysis 8. Other chronic respiratory pathology (bronchiectasis, chronic obstructive pulmonary disease, pulmonary fibrosis, etc.) 9. Any other uncontrolled chronic pathology, the presence of which would be considered incompatible with the performance of the study by the investigator 10. Patient under guardianship, curatorship or legal protection